PAT [1] for the quarter and nine months FY26 was ₹ 55.56 Cr. and ₹ 154.08 Cr. respectively. The PAT [1] of the above periods grew by 23.7% and 30.7% respectively, on Y-o-Y basis.
Ahmedabad, February 02, 2026: CORONA Remedies Limited, today announced the unaudited results for the third quarter and nine months ended December 31, 2025, as approved by its Board of Directors.
Q3 FY26 Financial Highlights:
| Particulars (₹ in Cr.) | Q3 FY26 | Nine Months
FY26 |
| Revenue from Operations | 342.42 | 1,050.09 |
| EBITDA | 83.16 | 231.42 |
| EBITDA Margin | 24.3% | 22.0% |
| Profit After Tax [1] | 55.56 | 154.08 |
| Profit After Tax Margin [1] | 16.2% | 14.7% |
Nine Months FY26 Key Financial Metrics:
| Particulars | Nine Months FY26 |
| RoE[1] [2] | 31.1% |
| RoCE[1] [2] | 48.0% |
| OCF to EBITDA | 86.3% |
| Net Working Capital Days | 18 Days |
[1] Excludes onetime statutory impact of New Labour Code ₹ 19.10 Cr. (Post Tax ₹14.29 Cr.) [2] Annualised
Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said:
“We are delighted to report a strong financial performance in Q3 and 9MFY26. Revenues for Q3 and 9MFY26 grew by 15.0% and 16.3% respectively on a Y-o-Y basis, outperforming the IPM growth. Adjusted Profit after tax for Q3 and 9MFY26 grew by 23.7% and 30.7% respectively on a Y-o-Y basis while maintaining healthy return ratios. We have been consistently delivering on our guided
We have transformed our aspiration of growing Revenues by 15% and PAT by 20% into successful achievement. Our revenues & PAT has grown as per our aspiration in the last 3 quarters and are optimistic of maintaining similar trajectory going forward.
Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists’ prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.
I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.”
Earnings Call:
CORONA Remedies Limited will conduct earnings call at 04:00 PM (IST) on February 03, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.
| Date & Time | Tuesday, February 03, 2026, 4:00pm IST
(HK/Singapore – 6:30 pm, UK – 10:30 am, USA – 5:30 am ET) |
| Universal Dial In | +91-22-6280 1259 / +91-22-7115 8160 |
| International Dial In | USA: 1 866 746 2133
UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
| Diamond Pass Link | https://services.choruscall.in/DiamondPassRegistration/register?confirmati onNumber=1267675&linkSecurityString=a117abdc0 |
